Key result
Current zolpidem use in women was associated with a significantly increased risk of acute pyelonephritis compared with never use (adjusted OR 2.2; 95% CI 1.7-2.8).
Why the study?
Does zolpidem use increase the risk of acute pyelonephritis in women?
Case-Control (n=9,166)
Does zolpidem use increase the risk of acute pyelonephritis in women?
Current use of zolpidem in women is associated with a significantly increased risk of acute pyelonephritis, warranting caution during prescribing.
Should not yet change zolpidem prescribing in women; hypothesis-generating and requires prospective validation.
The aim of this study was to assess a possible correlation between zolpidem use and acute pyelonephritis (APN) in women in Taiwan. Therefore, we performed a case-control study involving the Taiwan's National Health Insurance Research Database between 2000 and 2011. This study included 3151 female participants aged 20 to 84 years who experienced the first bout of APN (case group) and 6015 randomly selected female participants without APN (control group). Zolpidem use was defined as "current," "early," or "late," if the last remaining 1 tablet for zolpidem was detected within 7 days, between 8 and 14 days, or ≥15 days before the date of APN diagnosis, respectively. The multivariable unconditional logistic regression model was used to calculate the odds ratios (ORs) with 95% confidence intervals (CIs) to assess the correlation between zolpidem use and APN. After adjusting for confounders, the multivariable analysis yielded an adjusted APN OR of 2.2 for participants with current zolpidem use (95%CI 1.7-2.8) compared with participants who never used zolpidem. The adjusted ORs gradually decreased to 1.4 for participants with early zolpidem use (95%CI 0.8-2.5) and 1.1 for participants with late zolpidem use (95%CI 0.9-1.2), but without statistical significance. Only patients with current zolpidem use had a significantly increased relative risk of APN. Additional large confirmatory studies are needed to illustrate a causal relationship. Meanwhile, physicians and pharmacists should be more cautious about the risk of APN when prescribing and dispensing zolpidem in women.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2016) conducted a case-control in Acute pyelonephritis (n=9,166). Zolpidem use vs. Never used zolpidem was evaluated on Acute pyelonephritis (APN) (OR 2.2, 95% CI 1.7-2.8). Current zolpidem use in women was associated with a significantly increased risk of acute pyelonephritis compared with never use (adjusted OR 2.2; 95% CI 1.7-2.8).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: